liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries
Linköping University, Department of Clinical and Experimental Medicine, Clinical Microbiology. Linköping University, Faculty of Health Sciences.
National Centre for Antimicrobials and Infection Control.
Helsinki University Hospital.
University Hospital N Norway.
2011 (English)In: Scandinavian Journal of Infectious Diseases, ISSN 0036-5548, Vol. 43, no 9, 707-713 p.Article in journal (Refereed) Published
Abstract [en]

Background: This study involves a multicentre surveillance of tigecycline and tetracycline activity against Gram-negative and Gram-positive bacteria from primary care centres (PCCs), general hospital wards (GHWs) and intensive care units (ICUs) in Denmark (n = 9), Finland (n = 10), Norway (n = 7) and Sweden (n = 19). Methods: The hospitals were each asked to test 30 consecutive Gram-positive and 30 Gram-negative clinical isolates. Supportive information accompanying each isolate included the study centre, ward level (PCC, GHW, or ICU), patient identification and source of the isolate. Minimum inhibitory concentrations (MICs) for tetracycline and tigecycline were determined with the Etest. Results: The isolates collected comprised 1610 Gram-negative and 1767 Gram-positive clinical isolates. The study showed low rates of non-susceptibility (intermediate (I) and resistant (R)) to tigecycline: andlt; 1% in Escherichia coli, though other Enterobacteriaceae showed higher rates (Enterobacter cloacae (7%), Klebsiella pneumoniae (9%) and Serratia spp. (23%)). The overall non-susceptibility rate for tigecycline in Enterobacteriaceae with species-related breakpoints for tigecycline was 6% (4% excluding Serratia spp.). The activity of tigecycline against Haemophilus influenzae and Acinetobacter spp. was high with a MIC(50) of 0.25 mg/l and MIC(90) of 1 mg/l. The prevalence of non-susceptibility to tigecycline among Gram-positive bacteria was andlt; 1%. The corresponding figure for tetracycline was 14%. The activity of tigecycline against Streptococcus pneumoniae was high with MIC(50) and MIC(90) of 0.125 mg/l. Conclusion: Tigecycline showed good overall in vitro activity against Gram-positive and Gram-negative isolates, including both tetracycline-susceptible and resistant isolates. Most non-susceptibility to tigecycline among Enterobacteriaceae other than E. coli was I (6%), rather than R (andlt; 1%). This indicates a problem setting interpretive species-related tigecycline breakpoints for Enterobacteriaceae other than E. coli.

Place, publisher, year, edition, pages
Informa Healthcare , 2011. Vol. 43, no 9, 707-713 p.
Keyword [en]
Tigecycline, tetracycline, multicentre study, Gram-positive, Gram-negative, cross-resistance
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-70324DOI: 10.3109/00365548.2011.581305ISI: 000293913800006OAI: diva2:438353
Funding Agencies|Pfizer||Available from: 2011-09-02 Created: 2011-09-02 Last updated: 2011-09-02

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Nilsson, Lennart E
By organisation
Clinical MicrobiologyFaculty of Health Sciences
In the same journal
Scandinavian Journal of Infectious Diseases
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 54 hits
ReferencesLink to record
Permanent link

Direct link